Cancer progression results from activation of various signaling networks. Among these,
PI3K/Akt signaling contributes to proliferation, invasion, and inhibition of apoptosis …

Progressive liver fibrosis, induced by chronic viral and metabolic disorders, leads to more
than one million deaths annually via development of cirrhosis, although no antifibrotic …

Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. Cancer-associated
fibroblasts (CAFs) are recognized potential therapeutic targets, but poor understanding of …

Iterative liver injury results in progressive fibrosis disrupting hepatic architecture,
regeneration potential, and liver function. Hepatic stellate cells (HSCs) are a major source of …

Primary liver cancer is the second leading cause of cancer-related death worldwide and
therefore a major public health challenge. We review hypotheses of the cell of origin of liver …

Patients who develop chronic fibrotic liver disease, caused by viral or metabolic aetiologies,
are at a high risk of develo** hepatocellular carcinoma (HCC). Even after complete HCC …

Animal models are crucial for improving our understanding of human pathogenesis,
enabling researchers to identify therapeutic targets and test novel drugs. In the current …

The incidence of hepatocellular carcinoma (HCC) is rapidly increasing due to the
prevalence of obesity and non-alcoholic fatty liver disease, but the molecular triggers that …

With the emergence of genomic profiling technologies and selective molecular targeted
therapies, biomarkers play an increasingly important role in the clinical management of …

Non-alcoholic fatty liver disease—the most common chronic liver disease—encompasses a
histological spectrum ranging from simple steatosis to non-alcoholic steatohepatitis (NASH) …